Jefferies Keeps Their Hold Rating on Mesoblast Limited (MEOBF)
TipRanks (Mon, 3-Mar 7:18 AM ET)
Buy Rating for Mesoblast Driven by Promising Market Position and Strong Financial Backing
TipRanks (Fri, 28-Feb 3:15 PM ET)
Mesoblast Reports FDA Approval and Financial Results
TipRanks (Thu, 27-Feb 11:36 PM ET)
Globe Newswire (Wed, 26-Feb 5:30 PM ET)
Mesoblast Financial Results and Corporate Update Webcast
Globe Newswire (Tue, 25-Feb 6:13 PM ET)
Dr. Gregory George MD PhD Joins Mesoblast Board
Globe Newswire (Sun, 23-Feb 6:33 PM ET)
Presenting on the Emerging Growth Conference 79 Day 2 on February 19 Register Now
Globe Newswire (Wed, 19-Feb 6:00 AM ET)
Presenting on the Emerging Growth Conference 79 Day 1 on February 18 Register Now
Globe Newswire (Tue, 18-Feb 7:00 AM ET)
Ryoncil FDA Approval and Market Launch Highlighted at Tandem Transplantation Meetings
Globe Newswire (Thu, 13-Feb 6:37 PM ET)
Ryoncil Commercial Launch Update and Product Pipeline
Globe Newswire (Thu, 30-Jan 7:11 PM ET)
Mesoblast Ltd is a biotechnology company. It uses its proprietary technology platform to develop and commercialize allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care and where inflammation plays a central role. The company's product candidates include; Ryoncil (remestemcel-L) for the treatment of steroid refractory acute graft versus host disease as well as for the treatment of moderate to severe acute respiratory distress syndrome; Revascor (rexlemestrocel-L) for the treatment of chronic heart failure; and Rexlemestrocel-L for chronic low back pain. The company is managed as one operating segment, being the development of cell technology platform for commercialization.
Mesoblast Limited - American Depositary Shares trades on the NASDAQ stock market under the symbol MESO.
As of March 3, 2025, MESO stock price declined to $15.34 with 367,205 million shares trading.
MESO has a beta of 1.23, meaning it tends to be more sensitive to market movements. MESO has a correlation of 0.02 to the broad based SPY ETF.
MESO has a market cap of $1.95 billion. This is considered a Small Cap stock.
In the last 3 years, MESO traded as high as $22.00 and as low as $1.61.
The top ETF exchange traded funds that MESO belongs to (by Net Assets): IBB, APIE, BIB, IBBQ.
MESO has outperformed the market in the last year with a return of +634.0%, while the SPY ETF gained +18.7%. In the last 3 month period, MESO beat the market returning +32.5%, while SPY returned -0.5%. However, in the most recent 2 weeks MESO has underperformed the stock market by returning -14.3%, while SPY returned -2.6%.
MESO support price is $16.41 and resistance is $17.89 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that MESO shares will trade within this expected range on the day.